Cymerus™ MSCs Effective in Preclinical Model of Sepsis
5 December 2019 Melbourne, Australia: Australian stem cell and regenerative medicine company, Cynata Therapeutics Limited (ASX: CYP), announced today that it has received positive efficacy data from preclinical studies of its Cymerus™ mesenchymal stem cells (MSCs) in a…
Read MoreCSL Continues to Advance R&D Capabilities
4 December 2019 Unique portfolio mix of plasma, cell and gene therapy, recombinant proteins and antibody assets highlighted at Research & Development Briefing. SYDNEY, Australia – CSL Limited (ASX:CSL; USOTC:CSLLY) is steadily advancing its Research & Development (R&D) pipeline…
Read MoreANDHealth Appoints Leading Global Healthcare Analyst & Strategist to Management Team
4 December 2019 ANDHealth today announced the appointment of leading healthcare communicator, analyst and strategist, Iain Scott, to the role of VP Stakeholder Engagement. A globally accomplished strategist, analyst and communicator, Iain has more than 20 years’ experience…
Read MoreDigital Health Revolution
4 December 2019 Research Australia and the BioMelbourne Network are championing a Digital Health Revolution for Australia. Embracing digital technologies provides the opportunity to improve health outcomes, promote wellbeing and a sustainable health system, but it is going…
Read MorePositive DARRT-1 Data in Late-Stage Prostate Cancer
2 December 2019 Sydney: Noxopharm (ASX: NOX), an Australian drug development company, reports positive end-of-study data from its DARRT-1 Phase 1b trial. Commentary: Noxopharm Executive Chairman and CEO, Graham Kelly PhD “This is exciting data that validates our…
Read MoreOpthea Raises A$50 million in Institutional Placement
2 December 2019 Melbourne, Australia – Opthea Limited (Opthea or the Company) (ASX: OPT), a clinical-stage biopharmaceutical company developing novel biologic therapies to treat back-of-the-eye diseases, today announced that the company has received commitments from sophisticated and institutional…
Read More
